Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury

Rhea-AI Summary

Quince Therapeutics, Inc. (QNCX) showcased its innovative bone-targeting platform at the Military Health System Research Symposium 2022. The company's lead compound, NOV004, exhibited potential to accelerate healing in traumatic bone injuries, reducing healing time by 50% in animal models. Quince's approach targets bone fractures directly, offering a unique solution in a market lacking FDA-approved systemic therapies for fracture repair. The company plans to advance NOV004 into Phase 1 clinical studies in 2023, focusing on osteogenesis imperfecta and other significant bone diseases.

Positive

• NOV004 demonstrated a 50% decrease in fracture healing time in preclinical studies.
• The drug showed significant improvements in bone deposition and strength in animal models.
• Quince's targeting approach presents a novel solution for treating common fractures, filling a gap in available systemic therapies.

Negative

• None.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company’s participation at the Military Health System Research Symposium (MHSRS 2022), which took place September 12 to September 15, 2022, in Kissimmee, Florida. At MHSRS 2022, Quince presented a poster showcasing the broad applicability of the company’s highly differentiated bone-targeting platform and potential to accelerate healing directly at the site of bone injury in traumatic indications.

Stewart Low, Ph.D., Quince’s head of discovery, said, “As we continue to leverage and expand our core bone-targeting platform across promising indications, we believe there is an opportunity to introduce a novel method for accelerating the healing of traumatic bone injury. By concentrating at the site of injury, preclinical studies show that our lead NOV004 molecule can serve as a targeted potent bone growth stimulating drug that can dramatically shorten broken bone healing times and improve overall patient outcomes.”

MHSRS 2002 Poster Highlights

The following are highlights from the company’s poster presentation of preclinical data of NOV004 at MHSRS 2022:

Poster: Engineered Bone Fracture Targeted Parathyroid Hormone Agonist as an Effective Pharmaceutical for Accelerated Bone Repair in Mouse and Canine Models

• Each year in the U.S., there are more than 18 million fractures leading to more than $50 billion in direct medical costs. NOV004 is a fracture-targeted bone anabolic agent that concentrates selectively on the bone fracture surface and induces accelerated bone formation only at the damaged site.
• Quince believes that the systemic administration of NOV004 could provide a potential opportunity to treat stress fractures, multisite trauma, as well as operative and nonoperative fractures. There are currently no FDA approved systemic therapies for fracture repair.
• In preclinical studies, Quince observed a decrease in fracture healing time by 50% in NOV004 treated groups. Additionally, bone deposition and max load doubled and the force required to refracture the bones increased more than two-fold in mouse models.

To view the poster presented at MHSRS 2022, please visit the Science section of Quince’s corporate website.

About Quince Therapeutics

Quince Therapeutics is focused on advancing innovative precision therapeutics targeting debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Quince’s discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications to address underserved therapeutic areas with major, unmet medical needs, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases. The company’s lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, which preclinical studies demonstrate result in rapid increases in bone density, strength, and healing directly at the site of bone fracture. NOV004 is expected to enter Phase 1 clinical studies in 2023 and advance to a lead indication in osteogenesis imperfecta. For more information, visit www.quincetx.com and follow Quince Therapeutics on LinkedIn and @Quince_Tx on Twitter.

Forward-looking Statements

Statements in this news release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this news release may be identified by the use of words such as “anticipate,” “expect,” “will,” “can,” “may,” “should,” “estimate,” “project,” “potential,” “encouraged,” “positioned,” or other similar words. Examples of forward-looking statements include, among others, the clinical development and strategic development path for NOV004; the timing and success of the company’s clinical trials and related data, including plans and the ability to initiate, conduct and/or complete the Phase 1 clinical studies for NOV004; the potential therapeutic benefits, safety, and efficacy of the company’s bone-targeting platform, product candidate and discovery pipeline. Forward-looking statements are based on Quince Therapeutics’ current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2022, its Quarterly Report on Form 10-Q filed with the SEC on August 9, 2022, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince Therapeutics undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220916005037/en/

Quince Therapeutics Contact:

Stacy Roughan

Quince Therapeutics, Inc.

Vice President, Corporate Communications & Investor Relations

ir@quincetx.com

Source: Quince Therapeutics, Inc.

FAQ

What is the purpose of NOV004 in Quince Therapeutics' research?

NOV004 is designed to accelerate the healing of traumatic bone injuries by targeting the fracture site directly.

What were the results of the preclinical studies for NOV004?

Preclinical studies showed a 50% reduction in fracture healing time and significant improvements in bone strength and deposition.

When will NOV004 enter clinical trials?

Quince Therapeutics plans to initiate Phase 1 clinical studies for NOV004 in 2023.

How does Quince Therapeutics' platform differ from existing treatments?

Quince's platform specifically targets bone fractures, addressing a significant unmet need as there are currently no FDA-approved systemic therapies for fracture repair.

What are the implications of Quince's research for the market?

If successful, NOV004 could revolutionize fracture treatment, providing a new therapeutic option in a market with high medical costs associated with fractures.